BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sood A, Ahuja V, Midha V, Sinha SK, Pai CG, Kedia S, Mehta V, Bopanna S, Abraham P, Banerjee R, Bhatia S, Chakravartty K, Dadhich S, Desai D, Dwivedi M, Goswami B, Kaur K, Khosla R, Kumar A, Mahajan R, Misra SP, Peddi K, Singh SP, Singh A. Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 2020;18:355-78. [PMID: 32646198 DOI: 10.5217/ir.2019.09176] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
2 Wen N, Zhao N, Xu H, Zhao Y, Ma J. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment. Ir J Med Sci 2021. [PMID: 34843071 DOI: 10.1007/s11845-021-02837-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kim YS. Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators. J Korean Med Assoc 2021;64:596-604. [DOI: 10.5124/jkma.2021.64.9.596] [Reference Citation Analysis]